|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
IL136805A0
(en)
*
|
1997-12-22 |
2001-11-25 |
Euro Celtique Sa |
A method of preventing abuse of opioid dosage forms
|
|
DK1041987T3
(da)
|
1997-12-22 |
2006-08-21 |
Euro Celtique Sa |
Oral farmaceutisk doseringsform omfattende en kombination af en opioid-agonist og naltrexon
|
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
|
EP1623703B1
(en)
|
1999-10-29 |
2011-10-05 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
|
US6696088B2
(en)
*
|
2000-02-08 |
2004-02-24 |
Euro-Celtique, S.A. |
Tamper-resistant oral opioid agonist formulations
|
|
HU230875B1
(hu)
|
2000-10-30 |
2018-11-29 |
Euro-Celtique S.A. |
Szabályozott hatóanyag-leadású hidrokodon készítmények
|
|
US7858118B2
(en)
*
|
2001-04-11 |
2010-12-28 |
Galephar Pharmaceutical Research, Inc. |
Extended release composition containing Tramadol
|
|
EP1389092B1
(en)
*
|
2001-05-11 |
2006-11-15 |
Endo Pharmaceuticals Inc. |
Abuse-resistant opioid dosage form
|
|
DE60238756D1
(de)
*
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
|
US7968119B2
(en)
*
|
2001-06-26 |
2011-06-28 |
Farrell John J |
Tamper-proof narcotic delivery system
|
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
|
CN1551770A
(zh)
|
2001-07-06 |
2004-12-01 |
������ҩ������˾ |
羟吗啡酮控释制剂
|
|
PL208484B1
(pl)
|
2001-07-06 |
2011-05-31 |
Penwest Pharmaceuticals Company |
Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu
|
|
ATE419039T1
(de)
*
|
2001-07-18 |
2009-01-15 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
|
US20150031718A1
(en)
*
|
2001-08-06 |
2015-01-29 |
Purdue Pharma L.P. |
Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
|
|
US7157103B2
(en)
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
|
US7332182B2
(en)
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
US7141250B2
(en)
*
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
|
US7144587B2
(en)
*
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
|
AU2002323032B2
(en)
|
2001-08-06 |
2005-02-24 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
|
AU2002324624A1
(en)
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
US20030049317A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Lindsay David R. |
Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations
|
|
WO2003026743A2
(en)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
|
JP4814488B2
(ja)
|
2001-10-18 |
2011-11-16 |
ネクター セラピューティックス |
重合体共役物オピオイドアンタゴニスト
|
|
JP2005508372A
(ja)
*
|
2001-11-02 |
2005-03-31 |
エラン コーポレーシヨン ピーエルシー |
薬剤組成物
|
|
US20060177381A1
(en)
*
|
2002-02-15 |
2006-08-10 |
Howard Brooks-Korn |
Opiopathies
|
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
|
KR100822498B1
(ko)
*
|
2002-02-22 |
2008-04-16 |
샤이어 엘엘씨 |
규제된 물질의 남용을 방지하기 위한 새로운 서방성 약학화합물
|
|
US20030229111A1
(en)
*
|
2002-03-14 |
2003-12-11 |
Benjamin Oshlack |
Naltrexone hydrochloride compositions
|
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
|
GB0206505D0
(en)
*
|
2002-03-19 |
2002-05-01 |
Euro Celtique Sa |
Pharmaceutical combination
|
|
PT1578350E
(pt)
*
|
2002-03-26 |
2009-08-27 |
Euro Celtique Sa |
Composições revestidas com geles de libertação constante
|
|
PT1492505E
(pt)
*
|
2002-04-05 |
2015-10-06 |
Euro Celtique Sa |
Preparação farmacêutica contendo oxicodona e naloxona
|
|
CN100553625C
(zh)
|
2002-04-09 |
2009-10-28 |
弗拉梅技术公司 |
活性成分微囊的口服混悬液
|
|
MXPA04009979A
(es)
*
|
2002-04-09 |
2004-12-13 |
Flamel Tech Sa |
Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxicilina.
|
|
MXPA04010612A
(es)
|
2002-04-23 |
2005-07-14 |
Alza Corp |
Sistemas analgesicos transdermicos con potencial reducido de abuso.
|
|
US20040156844A1
(en)
*
|
2002-05-22 |
2004-08-12 |
Curtis Wright |
Tamper resistant oral dosage form
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
|
US8840928B2
(en)
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
AU2003247876B2
(en)
*
|
2002-07-05 |
2006-10-05 |
Collegium Pharmaceutical, Inc |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
US20060110333A1
(en)
*
|
2002-07-11 |
2006-05-25 |
Taiho Pharmaceutical Co., Ltd. |
Composition for nasal absorption
|
|
US8679533B2
(en)
|
2002-07-25 |
2014-03-25 |
Pharmacia Corporation |
Pramipexole once-daily dosage form
|
|
DE10237056A1
(de)
*
|
2002-08-09 |
2004-03-04 |
Grünenthal GmbH |
Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin
|
|
CA2495564A1
(en)
*
|
2002-08-15 |
2005-01-27 |
Euro-Celtique S.A. |
Pharmaceutical compositions
|
|
EP1545468A4
(en)
*
|
2002-09-20 |
2007-06-20 |
Alpharma Inc |
SUSTAINED RELEASE OPIOID PREPARATIONS AND METHODS OF USE
|
|
HUE038446T2
(hu)
|
2002-09-20 |
2018-10-29 |
Alpharma Pharmaceuticals Llc |
Szekvesztráló alegység és releváns kompozíciók és módszerek
|
|
EP1551402A4
(en)
*
|
2002-09-23 |
2009-05-27 |
Verion Inc |
PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
|
|
DE10250084A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
JP2006504491A
(ja)
|
2002-10-31 |
2006-02-09 |
ユーロ−セルティーク エス．エイ． |
医薬製品の識別
|
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
|
US7524515B2
(en)
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
|
DE10305137A1
(de)
*
|
2003-02-07 |
2004-08-26 |
Novosis Ag |
Transdermale therapeutische Abgabesysteme mit einem Butenolid
|
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
WO2004093819A2
(en)
|
2003-04-21 |
2004-11-04 |
Euro-Celtique, S.A. |
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
|
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
MXPA05011557A
(es)
|
2003-04-29 |
2006-03-09 |
Orexigen Therapeutics Inc |
Composiciones para afectar perdida de peso.
|
|
KR101159828B1
(ko)
*
|
2003-04-30 |
2012-07-04 |
퍼듀 퍼머 엘피 |
활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
|
|
US8790689B2
(en)
*
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
DE10361596A1
(de)
*
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
US20070183980A1
(en)
*
|
2003-08-06 |
2007-08-09 |
Elisabeth Arkenau-Maric |
Dosage form that is safeguarded from abuse
|
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
DE10336400A1
(de)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
US20060194826A1
(en)
*
|
2003-09-25 |
2006-08-31 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
|
EP1663229B1
(en)
*
|
2003-09-25 |
2010-04-14 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
|
US20050245557A1
(en)
*
|
2003-10-15 |
2005-11-03 |
Pain Therapeutics, Inc. |
Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
|
|
AU2004281153A1
(en)
*
|
2003-10-15 |
2005-04-28 |
Pain Therapeutics, Inc. |
Treatment of arthritic conditions, chronic inflammation or pain
|
|
CA2543610A1
(en)
|
2003-10-30 |
2005-05-19 |
Alza Corporation |
Transdermal analgesic systems having reduced abuse potential
|
|
US8883204B2
(en)
*
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
|
PT1691892E
(pt)
*
|
2003-12-09 |
2007-05-31 |
Euro Celtique Sa |
Forma posológica co-extrusada inviolável que contém um componente activo e um componente de acção contrária e um processo para a sua fabricação
|
|
TWI350762B
(en)
*
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
|
BRPI0507210A
(pt)
*
|
2004-02-23 |
2007-06-12 |
Euro Celtique Sa |
dispositivo que impede o uso indevido para administração transdérmica de opióide
|
|
TWI365880B
(en)
|
2004-03-30 |
2012-06-11 |
Euro Celtique Sa |
Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
|
|
JP2007530684A
(ja)
*
|
2004-03-30 |
2007-11-01 |
ユーロ−セルティーク エス．エイ． |
吸着剤と逆作用薬とを含有する不正使用防止投与剤型
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
DK1765292T3
(en)
|
2004-06-12 |
2018-01-02 |
Collegium Pharmaceutical Inc |
ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
|
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
CN101849920A
(zh)
*
|
2004-08-13 |
2010-10-06 |
贝林格尔·英格海姆国际有限公司 |
包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
|
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
|
GB2418854B
(en)
*
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
|
US7226619B1
(en)
|
2004-09-07 |
2007-06-05 |
Pharmorx Inc. |
Material for controlling diversion of medications
|
|
US7827983B2
(en)
*
|
2004-12-20 |
2010-11-09 |
Hewlett-Packard Development Company, L.P. |
Method for making a pharmaceutically active ingredient abuse-prevention device
|
|
BRPI0606339A2
(pt)
|
2005-01-28 |
2009-06-16 |
Euro Celtique Sa |
formas farmacêuticas resistentes a álcool
|
|
DE102005005449A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
FR2881652B1
(fr)
*
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
|
FR2889810A1
(fr)
*
|
2005-05-24 |
2007-02-23 |
Flamel Technologies Sa |
Forme medicamenteuse orale, microparticulaire, anti-mesurage
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
DE602006016441D1
(de)
|
2005-05-13 |
2010-10-07 |
Alza Corp |
Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
|
|
EP1879557A1
(en)
*
|
2005-05-13 |
2008-01-23 |
Alpharma, Inc. |
Morphine sulfate formulations
|
|
EP1895985A1
(en)
*
|
2005-05-13 |
2008-03-12 |
Alpharma, Inc. |
Morphine sulphate formulations
|
|
ES2277743B2
(es)
*
|
2005-06-02 |
2008-12-16 |
Universidade De Santiago De Compostela |
Nanoparticulas que comprenden quitosano y ciclodextrina.
|
|
WO2006133733A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Flamel Technologies |
Oral dosage form comprising an antimisuse system
|
|
EP1909769A2
(en)
*
|
2005-08-01 |
2008-04-16 |
Alpharma, Inc. |
Alcohol resistant pharmaceutical formulations
|
|
WO2007015243A2
(en)
|
2005-08-02 |
2007-02-08 |
Sol-Gel Technologies Ltd. |
Metal oxide coating of water insoluble ingredients
|
|
US8329744B2
(en)
*
|
2005-11-02 |
2012-12-11 |
Relmada Therapeutics, Inc. |
Methods of preventing the serotonin syndrome and compositions for use thereof
|
|
WO2008134071A1
(en)
*
|
2007-04-26 |
2008-11-06 |
Theraquest Biosciences, Inc. |
Multimodal abuse resistant extended release formulations
|
|
WO2007087452A2
(en)
*
|
2006-01-27 |
2007-08-02 |
Theraquest Biosciences, Llc |
Abuse resistant and extended release formulations and method of use thereof
|
|
US8652529B2
(en)
*
|
2005-11-10 |
2014-02-18 |
Flamel Technologies |
Anti-misuse microparticulate oral pharmaceutical form
|
|
EP2292220A3
(en)
|
2005-11-22 |
2012-01-04 |
Orexigen Therapeutics, Inc. |
Composition and methods for increasing insulin sensitivity
|
|
US9522188B2
(en)
|
2005-12-13 |
2016-12-20 |
Biodelivery Sciences International, Inc. |
Abuse resistant transmucosal drug delivery device
|
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
|
EP1810678A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
|
|
EP1810714A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution
|
|
CN101370485A
(zh)
*
|
2006-01-21 |
2009-02-18 |
艾博特股份有限两合公司 |
用于滥用药物给药的剂型和方法
|
|
US20070185145A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Royds Robert B |
Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
|
|
US7939567B2
(en)
*
|
2006-02-24 |
2011-05-10 |
Blue Blood Biotech Corp. |
Dextromethorphan-based method for treating acne
|
|
FR2898056B1
(fr)
|
2006-03-01 |
2012-01-20 |
Ethypharm Sa |
Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
|
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
|
ES2396039T3
(es)
|
2006-03-16 |
2013-02-18 |
Tris Pharma, Inc. |
Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
|
|
GB0606124D0
(en)
*
|
2006-03-28 |
2006-05-03 |
Reckitt Benckiser Healthcare |
Buprenorphine derivatives and uses thereof
|
|
JP5457830B2
(ja)
*
|
2006-04-03 |
2014-04-02 |
オディディ，イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
|
CA2661818A1
(en)
*
|
2006-05-03 |
2007-11-15 |
Kowa Pharmaceuticals America, Inc. |
Acute pain medications based on fast acting diclofenac-opioid combinations
|
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
|
DK2526932T3
(en)
|
2006-06-19 |
2017-07-17 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
US8765178B2
(en)
|
2006-07-19 |
2014-07-01 |
Watson Laboratories, Inc. |
Controlled release formulations and associated methods
|
|
EP2054031B1
(en)
|
2006-07-21 |
2016-04-06 |
BioDelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
|
AU2007275034A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
|
AU2011205222B2
(en)
*
|
2006-07-21 |
2014-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
EP1897543A1
(en)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine- wafer for drug substitution therapy
|
|
WO2008027442A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Theraquest Biosciences, Llc |
Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
|
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
|
US8187636B2
(en)
*
|
2006-09-25 |
2012-05-29 |
Atlantic Pharmaceuticals, Inc. |
Dosage forms for tamper prone therapeutic agents
|
|
JP2010506833A
(ja)
*
|
2006-10-11 |
2010-03-04 |
アルファーマ，インコーポレイテッド |
医薬組成物
|
|
AU2007319472B2
(en)
|
2006-11-09 |
2013-01-17 |
Nalpropion Pharmaceuticals Llc |
Methods Of Administering Weight Loss Medications
|
|
DE102006054731B4
(de)
|
2006-11-21 |
2013-02-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
|
|
EP2101740B1
(en)
|
2006-12-04 |
2013-11-06 |
Orexo AB |
New non-abusable pharmaceutical composition comprising opioids
|
|
AU2008211553B2
(en)
|
2007-02-01 |
2013-06-20 |
Sol-Gel Technologies Ltd. |
Compositions for topical application comprising a peroxide and retinoid
|
|
WO2008093347A2
(en)
|
2007-02-01 |
2008-08-07 |
Sol-Gel Technologies Ltd. |
Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
|
|
GB2447014A
(en)
*
|
2007-03-01 |
2008-09-03 |
Reckitt Benckiser Healthcare |
Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
|
|
WO2008109462A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Farnam Companies, Inc. |
Sustained release pellets comprising wax-like material
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
|
PL2187873T3
(pl)
|
2007-08-13 |
2019-01-31 |
Abuse Deterrent Pharmaceutical Llc |
Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
|
|
MX2010002409A
(es)
*
|
2007-09-03 |
2010-05-19 |
Nanotherapeutics Inc |
Composiciones y metodos para la distribucion de farmacos escasamente solubles.
|
|
US8486448B2
(en)
|
2007-12-17 |
2013-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
|
CA2709950A1
(en)
*
|
2007-12-17 |
2009-07-09 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
AU2015200313B2
(en)
*
|
2007-12-17 |
2016-12-01 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
AU2008346870A1
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
CA2709905A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alfred Liang |
Abuse-resistant oxycodone composition
|
|
EP2224806A4
(en)
*
|
2007-12-17 |
2014-02-19 |
Alpharma Pharmaceuticals Llc |
PHARMACEUTICAL COMPOSITION
|
|
EP2249811A1
(en)
|
2008-01-25 |
2010-11-17 |
Grünenthal GmbH |
Pharmaceutical dosage form
|
|
WO2009106831A2
(en)
*
|
2008-02-28 |
2009-09-03 |
Syntropharma Limited |
Pharmaceutical composition
|
|
KR101690094B1
(ko)
|
2008-05-09 |
2016-12-27 |
그뤼넨탈 게엠베하 |
분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
|
|
US20110144145A1
(en)
|
2008-05-30 |
2011-06-16 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
|
RU2478388C2
(ru)
*
|
2008-07-07 |
2013-04-10 |
Еуро-Селтик С.А. |
Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
|
|
WO2010044842A1
(en)
*
|
2008-10-16 |
2010-04-22 |
University Of Tennessee Research Foundation |
Tamper resistant oral dosage forms containing an embolizing agent
|
|
AU2009340504A1
(en)
*
|
2008-10-30 |
2010-08-26 |
Grunenthal Gmbh |
Novel and potent tapentadol dosage forms
|
|
US8460640B2
(en)
*
|
2008-12-12 |
2013-06-11 |
Paladin Labs, Inc. |
Narcotic drug formulations with decreased abuse potential
|
|
ES2509497T3
(es)
|
2008-12-16 |
2014-10-17 |
Paladin Labs Inc. |
Formulación de liberación controlada para evitar un uso indebido
|
|
AU2009332963B2
(en)
|
2008-12-31 |
2015-02-05 |
Upsher-Smith Laboratories, Llc |
Opioid-containing oral pharmaceutical compositions and methods
|
|
US20120065221A1
(en)
*
|
2009-02-26 |
2012-03-15 |
Theraquest Biosciences, Inc. |
Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
|
|
KR20110133602A
(ko)
|
2009-03-10 |
2011-12-13 |
유로-셀티큐 에스.에이. |
옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
|
|
JP2012524732A
(ja)
*
|
2009-04-22 |
2012-10-18 |
フェーメ ゲーエムベーハー |
オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
|
|
GB0909680D0
(en)
|
2009-06-05 |
2009-07-22 |
Euro Celtique Sa |
Dosage form
|
|
SI2456424T1
(sl)
*
|
2009-07-22 |
2013-10-30 |
Gruenenthal Gmbh |
Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo
|
|
AR077493A1
(es)
|
2009-07-22 |
2011-08-31 |
Gruenenthal Gmbh |
Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
|
|
AU2009352681B2
(en)
|
2009-09-17 |
2014-11-20 |
Upsher-Smith Laboratories, Llc |
A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
|
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
CN102724878A
(zh)
|
2010-01-11 |
2012-10-10 |
奥雷西根治疗公司 |
在重度抑郁症患者中提供体重减轻疗法的方法
|
|
EP2531176B1
(en)
|
2010-02-03 |
2016-09-07 |
Grünenthal GmbH |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
|
US20120321716A1
(en)
|
2011-02-17 |
2012-12-20 |
Michael Vachon |
Technology for preventing abuse of solid dosage forms
|
|
CA2792878C
(en)
|
2010-03-12 |
2019-10-22 |
Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services |
Agonist/antagonist compositions and methods of use
|
|
US9700508B2
(en)
*
|
2010-05-10 |
2017-07-11 |
Euro-Celtique S.A. |
Pharmaceutical compositions comprising hydromorphone and naloxone
|
|
US9993433B2
(en)
|
2010-05-10 |
2018-06-12 |
Euro-Celtique S.A. |
Manufacturing of active-free granules and tablets comprising the same
|
|
NZ603170A
(en)
*
|
2010-05-10 |
2015-04-24 |
Euro Celtique Sa |
Combination of active loaded granules with additional actives
|
|
WO2011143120A1
(en)
|
2010-05-11 |
2011-11-17 |
Cima Labs Inc. |
Alcoholres i stant metoprolol - containing extended - release oral dosage forms
|
|
PL2611425T3
(pl)
|
2010-09-02 |
2014-09-30 |
Gruenenthal Gmbh |
Odporna na ingerencję postać dawki zawierająca polimer anionowy
|
|
MX2013002377A
(es)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
|
|
DE102010048883A1
(de)
|
2010-10-19 |
2012-04-19 |
Lars Holger Hermann |
Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen
|
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
|
JP2012087101A
(ja)
*
|
2010-10-21 |
2012-05-10 |
Holger Hermann Lars |
オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
|
|
KR101647267B1
(ko)
|
2010-12-22 |
2016-08-09 |
퍼듀 퍼머 엘피 |
케이싱된 탬퍼 저항성 제어 방출 투여 형태
|
|
PH12013501345A1
(en)
|
2010-12-23 |
2022-10-24 |
Purdue Pharma Lp |
Tamper resistant solid oral dosage forms
|
|
PH12013501244A1
(en)
*
|
2010-12-28 |
2013-07-15 |
Euro Celtique Sa |
A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
|
|
CN102068697B
(zh)
*
|
2010-12-30 |
2013-10-16 |
宜昌人福药业有限责任公司 |
含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
|
|
US20140141090A1
(en)
|
2011-02-02 |
2014-05-22 |
Edward S. Wilson |
Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist
|
|
US20140127300A1
(en)
*
|
2011-06-30 |
2014-05-08 |
Neos Therapeutics, Lp |
Abuse resistant drug forms
|
|
EP2736497B1
(en)
|
2011-07-29 |
2017-08-23 |
Grünenthal GmbH |
Tamper-resistant tablet providing immediate drug release
|
|
JP2014524925A
(ja)
|
2011-07-29 |
2014-09-25 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時薬剤放出を提供するタンパーレジスタント錠剤
|
|
WO2013026064A1
(en)
|
2011-08-18 |
2013-02-21 |
Biodelivery Sciences International, Inc. |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
|
PL2915525T3
(pl)
|
2011-09-19 |
2022-01-17 |
Orexo Ab |
Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
|
|
US20150265536A1
(en)
*
|
2011-12-09 |
2015-09-24 |
Purdue Pharma L.P. |
Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
|
|
SG10201604754VA
(en)
|
2011-12-12 |
2016-08-30 |
Lohmann Therapie Syst Lts |
Transdermal delivery system comprising buprenorphine
|
|
UA118540C2
(uk)
*
|
2011-12-21 |
2019-02-11 |
Біоделівері Сайєнсиз Інтернешнл, Інк. |
Пристрої для трансмукозальної доставки ліків для застосування у полегшенні хронічного болю
|
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
|
MX356421B
(es)
|
2012-02-28 |
2018-05-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
|
|
US9687445B2
(en)
|
2012-04-12 |
2017-06-27 |
Lts Lohmann Therapie-Systeme Ag |
Oral film containing opiate enteric-release beads
|
|
NZ631539A
(en)
|
2012-04-17 |
2016-10-28 |
Purdue Pharma Lp |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
|
AR090695A1
(es)
|
2012-04-18 |
2014-12-03 |
Gruenenthal Gmbh |
Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
US8802658B2
(en)
|
2012-05-14 |
2014-08-12 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9662343B2
(en)
|
2012-05-14 |
2017-05-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9956238B2
(en)
|
2014-05-15 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9901589B2
(en)
|
2012-05-14 |
2018-02-27 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10413560B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US10350227B2
(en)
|
2012-05-14 |
2019-07-16 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10039773B2
(en)
|
2012-05-14 |
2018-08-07 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating arthritis
|
|
US9827256B2
(en)
|
2014-05-27 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating lower back pain
|
|
US9861648B2
(en)
|
2012-05-14 |
2018-01-09 |
Antecip Boiventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US10413561B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US9943531B2
(en)
|
2014-08-08 |
2018-04-17 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9675626B2
(en)
|
2012-05-14 |
2017-06-13 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9717747B2
(en)
|
2012-05-14 |
2017-08-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9867839B2
(en)
|
2012-05-14 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US10080765B2
(en)
|
2012-05-14 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10016446B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
|
|
US9211257B2
(en)
|
2012-05-14 |
2015-12-15 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9770457B2
(en)
|
2012-05-14 |
2017-09-26 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesion
|
|
US9616078B2
(en)
|
2012-05-14 |
2017-04-11 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9820999B2
(en)
|
2012-05-14 |
2017-11-21 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10111837B2
(en)
|
2012-05-14 |
2018-10-30 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds
|
|
US9895383B2
(en)
|
2012-05-14 |
2018-02-20 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10493085B2
(en)
|
2012-05-14 |
2019-12-03 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US9827192B2
(en)
|
2012-05-14 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10028908B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9289441B2
(en)
|
2014-08-08 |
2016-03-22 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US10092581B2
(en)
|
2014-05-15 |
2018-10-09 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9782421B1
(en)
|
2012-05-14 |
2017-10-10 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US9427403B2
(en)
|
2012-05-14 |
2016-08-30 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US10463682B2
(en)
|
2012-05-14 |
2019-11-05 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
|
|
US10034890B2
(en)
|
2012-05-14 |
2018-07-31 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9789128B2
(en)
|
2012-05-14 |
2017-10-17 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10016445B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9655908B2
(en)
|
2012-05-14 |
2017-05-23 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US9949993B2
(en)
|
2012-05-14 |
2018-04-24 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9707245B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10173986B2
(en)
|
2012-05-14 |
2019-01-08 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9999628B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9707247B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US10028969B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9925203B2
(en)
|
2012-05-14 |
2018-03-27 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9867840B2
(en)
|
2014-05-27 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9694023B2
(en)
|
2012-05-14 |
2017-07-04 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9877977B2
(en)
|
2012-05-14 |
2018-01-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9956237B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US11654152B2
(en)
|
2012-05-14 |
2023-05-23 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
US10004756B2
(en)
|
2014-05-15 |
2018-06-26 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9956234B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US9700570B2
(en)
|
2014-05-27 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US8865757B1
(en)
|
2014-05-28 |
2014-10-21 |
Antecip Bioventures Ii Llp |
Therapeutic compositions comprising imidazole and imidazolium compounds
|
|
US9669040B2
(en)
|
2012-05-14 |
2017-06-06 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9844559B2
(en)
|
2012-05-14 |
2017-12-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesions
|
|
US9795622B2
(en)
|
2012-05-14 |
2017-10-24 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating pain associated with a joint
|
|
US9999629B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
KR20220042241A
(ko)
|
2012-06-06 |
2022-04-04 |
오렉시젠 세러퓨틱스 인크. |
과체중 및 비만의 치료 방법
|
|
PL2872121T3
(pl)
|
2012-07-12 |
2019-02-28 |
SpecGx LLC |
Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
|
|
US9687465B2
(en)
|
2012-11-27 |
2017-06-27 |
Sol-Gel Technologies Ltd. |
Compositions for the treatment of rosacea
|
|
KR101659983B1
(ko)
|
2012-12-31 |
2016-09-26 |
주식회사 삼양바이오팜 |
용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
|
|
PE20151301A1
(es)
|
2013-02-05 |
2015-09-16 |
Purdue Pharma Lp |
Formulaciones farmaceuticas resistentes a la manipulacion indebida
|
|
US9517208B2
(en)
|
2013-03-15 |
2016-12-13 |
Purdue Pharma L.P. |
Abuse-deterrent dosage forms
|
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
|
US11571390B2
(en)
|
2013-03-15 |
2023-02-07 |
Othemo Life Sciences, Inc. |
Abuse deterrent compositions and methods of use
|
|
ITTO20130284A1
(it)
*
|
2013-04-09 |
2014-10-10 |
Fond Istituto Italiano Di Tecnologia |
Procedimento per la produzione di microparticelle polimeriche sagomate
|
|
US9737490B2
(en)
|
2013-05-29 |
2017-08-22 |
Grünenthal GmbH |
Tamper resistant dosage form with bimodal release profile
|
|
MX371432B
(es)
*
|
2013-05-29 |
2020-01-30 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
|
|
PT2810646T
(pt)
|
2013-06-04 |
2016-10-05 |
Lts Lohmann Therapie Systeme Ag |
Sistema de administração transdérmica
|
|
EA032465B1
(ru)
|
2013-07-12 |
2019-05-31 |
Грюненталь Гмбх |
Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
|
|
EA201600033A1
(ru)
|
2013-07-23 |
2016-10-31 |
Еуро-Селтик С.А. |
Комбинация оксикодона и налоксона для лечения боли у пациентов, страдающих от боли и заболевания, приводящего к дисбиозу кишечника и/или повышению риска транслокации кишечной микрофлоры
|
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
|
EP3062777A2
(en)
|
2013-10-31 |
2016-09-07 |
Cima Labs Inc. |
Abuse-deterrent dosage forms
|
|
US20150118300A1
(en)
|
2013-10-31 |
2015-04-30 |
Cima Labs Inc. |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
|
EA030310B1
(ru)
|
2013-11-13 |
2018-07-31 |
Эро-Селтик С.А. |
Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
|
|
BR112016010482B1
(pt)
|
2013-11-26 |
2022-11-16 |
Grünenthal GmbH |
Preparação de uma composição farmacêutica em pó por meio de criomoagem
|
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|
|
US9480644B2
(en)
|
2014-03-14 |
2016-11-01 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
EP3777838A1
(en)
|
2014-03-14 |
2021-02-17 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
US10085937B2
(en)
|
2014-03-14 |
2018-10-02 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
US9561177B2
(en)
|
2014-03-14 |
2017-02-07 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
MX2016014738A
(es)
|
2014-05-12 |
2017-03-06 |
Gruenenthal Gmbh |
Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
|
|
MX2016015417A
(es)
|
2014-05-26 |
2017-02-22 |
Gruenenthal Gmbh |
Multiparticulas protegidas contra vertido de dosis etanolico.
|
|
US9127069B1
(en)
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
|
US9682039B2
(en)
*
|
2014-08-07 |
2017-06-20 |
Mucodel Pharma Llc |
Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
|
|
US10493027B2
(en)
|
2014-08-07 |
2019-12-03 |
Mucodel Pharma Llc |
Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
US10729685B2
(en)
|
2014-09-15 |
2020-08-04 |
Ohemo Life Sciences Inc. |
Orally administrable compositions and methods of deterring abuse by intranasal administration
|
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
|
CA2970065A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
EP3229785A2
(de)
*
|
2014-12-08 |
2017-10-18 |
Develco Pharma Schweiz AG |
Naloxon-monopräparat und mehrschichttablette
|
|
FR3032353B1
(fr)
*
|
2015-02-06 |
2017-03-10 |
Jacques Seguin |
Composition pharmaceutique et dispositif pour le traitement de la douleur
|
|
EA035434B1
(ru)
|
2015-04-24 |
2020-06-15 |
Грюненталь Гмбх |
Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
|
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
|
WO2017039778A1
(en)
*
|
2015-08-31 |
2017-03-09 |
Regents Of The University Of Minnesota |
Opioid receptor modulators and use thereof
|
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
|
US20170065521A1
(en)
*
|
2015-09-09 |
2017-03-09 |
Micell Technologies, Inc. |
Biopharma application of micell technology
|
|
WO2017042325A1
(en)
|
2015-09-10 |
2017-03-16 |
Grünenthal GmbH |
Protecting oral overdose with abuse deterrent immediate release formulations
|
|
US9943513B1
(en)
|
2015-10-07 |
2018-04-17 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
|
GB201520390D0
(en)
*
|
2015-11-19 |
2016-01-06 |
Euro Celtique Sa |
Composition
|
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
|
CA2972220C
(en)
|
2016-06-29 |
2023-01-24 |
Disposerx, Inc. |
Disposal of medicaments
|
|
WO2018012627A1
(ja)
*
|
2016-07-15 |
2018-01-18 |
シャープ株式会社 |
送風装置および空気調和機
|
|
WO2018208241A1
(en)
*
|
2017-05-10 |
2018-11-15 |
İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi |
Formulation and optimization of controlled release tablets of morphine sulphate
|
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
|
KR20200022026A
(ko)
|
2017-06-30 |
2020-03-02 |
퍼듀 퍼머 엘피 |
치료 방법 및 이의 약형
|
|
HRP20251185T1
(hr)
|
2017-07-12 |
2025-11-21 |
Sol-Gel Technologies Ltd. |
Tvari koje obuhvaćaju tretinoin u kapsulama
|
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
|
US12458592B1
(en)
|
2017-09-24 |
2025-11-04 |
Tris Pharma, Inc. |
Extended release amphetamine tablets
|
|
CN111629758A
(zh)
*
|
2017-10-09 |
2020-09-04 |
罗兹制药公司 |
药物树脂化物组合物及其制备和使用方法
|
|
EP3473246A1
(en)
|
2017-10-19 |
2019-04-24 |
Capsugel Belgium NV |
Immediate release abuse deterrent formulations
|
|
JP7293209B2
(ja)
*
|
2017-10-20 |
2023-06-19 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
医薬剤形
|
|
WO2019126125A1
(en)
|
2017-12-20 |
2019-06-27 |
Purdue Pharma L.P. |
Abuse deterrent morphine sulfate dosage forms
|
|
US10624856B2
(en)
|
2018-01-31 |
2020-04-21 |
Dharma Laboratories LLC |
Non-extractable oral solid dosage forms
|
|
CN109232748B
(zh)
*
|
2018-09-26 |
2019-06-11 |
哈尔滨工业大学 |
多位点修饰的脑啡肽与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用
|
|
US20220105085A1
(en)
*
|
2019-01-31 |
2022-04-07 |
Relmada Therapeutics, Inc. |
Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist
|
|
WO2020225773A1
(en)
|
2019-05-07 |
2020-11-12 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
US20220273645A1
(en)
*
|
2019-07-10 |
2022-09-01 |
Intas Pharmaceuticals Ltd. |
Naltrexone formulation
|
|
IT201900013473A1
(it)
*
|
2019-07-31 |
2021-01-31 |
Vetagro Int S R L |
Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
|
|
EP3936112A1
(en)
*
|
2020-07-07 |
2022-01-12 |
Occlugel |
Hydrophilic degradable microspheres for delivering buprenorphine
|
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|
|
CA3247111A1
(en)
*
|
2022-01-26 |
2023-08-03 |
Aardvark Therapeutics, Inc. |
Extended-release oral formulation of liquid resin for the treatment of autism spectrum disorders
|
|
US12303604B1
(en)
|
2024-10-16 |
2025-05-20 |
Currax Pharmaceuticals Llc |
Pharmaceutical formulations comprising naltrexone and/or bupropion
|